

1 **TITLE PAGE**

2

3 **Full title:** Fluoroscopy time as a new predictor of short-term outcomes after transcatheter aortic
4 valve replacement

5

6 **Short title:** Fluoroscopy time as independent predictor in TAVR.

7

8 **Authors' names:** Alessandro Cafaro¹ MD (dr.alessandrocafar@libero.it) (0000-0002-2068-
9 7351), Francesco Spione^{2,3} MD (francesco.spio@gmail.com) (0000-0002-9327-5286), Osvaldo
10 Burattini⁴ MD (osvaldoburattini@gmail.com) (0000-0002-6904-5528), Daniele De Feo⁵ MD
11 (daniele.df93@gmail.com) (0000-0003-1055-0973), Alessandro Xhelo⁵ MD
12 (alessandroxhelo2@gmail.com) (0009-0002-5317-8489), Chiara Palmitessa⁵ MD
13 (chiara.palmy@gmail.com) (0000-0001-7575-9300), Maurizio D'Alessandro⁵ MD
14 (maurizio.dalessandro23@gmail.com) (0000-0002-4558-8157), Vincenzo Pio Amendola⁵ MD
15 (vincenzopioamendola@icloud.com) (0009-0002-7044-6916), Flavio Rimmaudo⁶ MD
16 (rimmaudoflavio@gmail.com) (0000-0001-9846-4564), Andrea Igoren Guaricci⁵, MD, PhD
17 (andrea.guaricci@gmail.com) (0000-0001-7133-4401), Alessandro Santo Bortone⁷ MD PhD
18 (alessandrosanto.bortone@uniba.it) (0000-0002-7086-7182), Vincenzo Pestrichella⁸ MD
19 (vpestrichella@yahoo.it), Gaetano Contegiacomo⁹ MD (gconteg@gmail.com) (0000-0002-3422-
20 7647), Tullio Tesorio² MD (tulliotesorio@gmail.com) (0000-0002-9118-4612), Giuseppe
21 Colonna¹ MD (giuseppe.colonna@tin.it), Fortunato Iacovelli^{4,5} MD PhD
22 (fortunato.iacovelli@gmail.com) (0000-0002-4620-678X).

23

24 **Authors' affiliations**

25 ¹ Division of Cardiology, “V. Fazzi” Hospital, Lecce, Italy

26 ² Interventional Cardiology Service, “Montevergine” Clinic, GVM Care & Research,
27 Mercogliano, Italy

28 ³ Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples
29 “Federico II”, Naples, Italy

30 ⁴ Division of Cardiology, “SS. Annunziata” Hospital, Taranto, Italy

31 ⁵ Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital,
32 Bari, Italy

33 ⁶ Division of Cardiology, “Vittorio Emanuele” Hospital, Gela, Italy

34 ⁷ Division of University Heart Surgery, Cardiothoracic Department, Policlinico University
35 Hospital, Bari, Italy

36 ⁸ Interventional Cardiology Service, “Mater Dei” Hospital, Bari, Italy

37 ⁹ Interventional Cardiology Service, “Anthea” Clinic, GVM Care & Research, Bari, Italy

38

39 All authors take responsibility for all aspects of the reliability and freedom from bias of the data
40 presented and their discussed interpretation.

41

42 **Funding:** This research received no external funding.

43 **Institutional Review Board Statement:** The study was conducted in accordance with the
44 Declara-tion of Helsinki, and approved by the Independent Ethics Committee of the Policlinico
45 University Hospital of Bari, Italy (study number 6244, protocol code 0030669 and date of
46 approval 04th of March 2020).”

47 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the
48 study.

49

50 **For correspondence:** Fortunato Iacovelli, MD PhD (*corresponding author*)

51 Division of University Cardiology, Cardiothoracic Department, Policlinico University Hospital,

52 Piazza Giulio Cesare 11, 70124 Bari, Italy

53 E-mail: fortunato.iacovelli@gmail.com Tel.: +393200931665 Fax: +390805478796

54

55

56 **Conflicts of interest:** Gaetano Contegiacomo serves as transcatheter heart valve proctor for

57 Abbott; Fortunato Iacovelli and Francesco Spione directly received speaker fees from General

58 Electric Healthcare; the remaining authors have no conflicts of interest to declare.

59

60 **ABSTRACT**

61

62 **Objective:** Transcatheter aortic valve replacement (TAVR) is a cine-fluoroscopic guided

63 procedure. The amount of radiation used during the procedure is strictly related with fluoroscopy

64 time (FT) that has been demonstrated to be associated with outcomes and complexity of

65 procedure in percutaneous coronary interventions. The aim of our study is to demonstrate the

66 relationship between FT and short-term outcomes after TAVR.

67 **Methods:** After splitting 1797 consecutive patients according to tertiles of FT, the composite

68 endpoint early safety (ES) was adjudicated according to Valve Academic Research Consortium

69 (VARC)-2 and -3 consensus documents and the composite endpoints of device success (DS) and
70 technical success (TS) according to VARC-3 criteria.

71 **Results:** The absence of all outcomes (TS, DS, and ES according to VARC-3 and ES according
72 to VARC-2) was significantly associated with higher FT and this association persisted after
73 propensity score matching analysis. Notwithstanding, after receiver operating characteristic
74 analysis, only the FT cut-offs identified for VARC-3 TS and VARC-2 ES had adequate
75 diagnostic accuracy in identifying the absence of these endpoints.

76 **Conclusions:** Longer FT is related with peri-procedural and short-term outcomes after the
77 procedure, especially in those that are more complex. A FT duration of more than 30 minutes has
78 an adequate accuracy in identifying VARC-3 technical failure and absence of VARC-2 ES.

79
80 **What is already known on this topic:** FT is related with complexity and outcomes in PCI. No
81 data is available about FT and TAVR.

82 **What this study adds:** FT >30 minutes has an adequate accuracy in identifying VARC-3
83 technical failure and absence of VARC-2 ES.

84 **How this study might affect research, practice or policy:** FT that lasts more than 30 minutes
85 in TAVR is linked independently to short-term adverse outcomes after TAVR. A strict follow-up
86 is needed in this procedural setting as FT is a new independent predictor of adverse outcome
87 after TAVR.

88
89 **Keywords:** aortic stenosis; transcatheter aortic valve implantation; fluoroscopy; technical
90 success; early safety; Valve Academic Research Consortium.

91

92 **TEXT**

93 **1. Introduction**

94 Transcatheter aortic valve replacement (TAVR) is an established treatment for pa-tients with
95 aortic valve stenosis at high surgical risk or considered inadequate for con-ventional surgical
96 aortic valve replacement (SAVR). Multiple observational and random-ized clinical trials have
97 demonstrated the feasibility and efficacy of this treatment [1-10]. Notwithstanding, recent
98 randomized trials have demonstrated that this percutaneous technique is non-inferior to SAVR
99 also in intermediate and low surgical risk patients [11-15].

100 TAVR is a cine-fluoroscopic guided procedure, and the amount of radiation used is potentially
101 dangerous for both operators and patients because of its stochastic and de-terministic adverse
102 effects [16,17]. The radiation dose, which is strictly related to fluoros-copy time and procedure
103 length, has been demonstrated to be similar to other percuta-neous coronary interventions of
104 moderate complexity [18-20].

105 To date, no study has investigated the association between FT and short-term prog-nosis after
106 TAVR. In particular, in the Valve Academic Research Consortium (VARC) documents [21,22],
107 early safety (ES) and device success (DS) are short-term composite endpoints. ES combines all-
108 cause mortality, all stroke, life-threatening bleeding, stage 2 or 3 acute kidney injury (AKI),
109 coronary artery obstruction requiring intervention, and valve-related dysfunction requiring
110 another aortic valvular procedure within 30 days after TAVR. DS combines the absence of
111 procedural mortality, correct positioning of a single prosthetic heart valve into the proper
112 anatomical location and intended performance of the prosthetic heart valve. The VARC-3
113 consensus document added the endpoint technical success (TS) which is a composite of freedom
114 from mortality, successful access, delivery of the device, and retrieval of the delivery system,

115 correct positioning of a single prosthetic heart valve into the proper anatomical location and
116 freedom from surgery or intervention related to the devices or to a major vascular or access-
117 related, or cardiac structural complications at the exit from procedure room [22]. With respect to
118 ES definition, the VARC-3 document added other adverse events that significantly impact short-
119 and long-term prognosis, such as cardiac structural complications, significant (moderate to
120 severe) aortic regurgitation, and new permanent pacemaker (PM) implantation [22]. Finally, the
121 definition of DS in the VARC-3 document added TS among the other endpoints included in the
122 VARC-2 definition [21,22].

123 Our study aims to evaluate for the first time, in a large population, the relationship between FT
124 and short-term outcomes after TAVR.

125

126 **2. Materials and Methods**

127 *2.1. Study population*

128 This multicenter observational study assessed all consecutive patients who under-went TAVR at
129 five southern Italy heart centers (“Montevergine” Clinic of Mercogliano, Policlinico University
130 Hospital, “Anthea” Clinic and “Mater Dei” Hospital of Bari and “V. Fazzi” Hospital of Lecce)
131 involved in the “Magna Graecia” TAVR registry.

132 Between March 2011 and April 2023, 1797 consecutive patients (785 males, mean age
133 80.86 ± 5.71 , 1703 transfemoral access) suitable for TAVR were enrolled. All patients underwent
134 preprocedural assessment with transthoracic echocardiography, coronary angiography, computed
135 tomography scan of the heart, aorta and peripheral arteries, carotid artery ultrasonography and
136 multidisciplinary evaluation by the Heart Team. The majority of procedures were performed in a
137 standard cardiac catheterization laboratory with the support of anesthesiology and surgical

138 backup by experienced operators. Device used were balloon-expandable valves (Edwards Sapien
139 XT and Sapien 3; Meril Myval), self-expandable valves (Medtronic CoreValve, Engager, Evolut
140 R and Evolut PRO; Abbott Portico) and others (Boston Lotus; Boston Acurate and Acurate neo;
141 Direct Flow Medical; JenaValve).

142 Each participating site collected all baseline demographics, clinical, laboratory,
143 echocardiographic, surgical risk score, intraprocedural and postprocedural data, in-hospital
144 outcomes and 1-month follow-up outcomes, in the same dedicated archiving software. All the
145 adverse events and the TS, DS and ES composite endpoints were also re-adjudicated
146 retrospectively, by an external committee of interventional cardiologists, according to both
147 VARC-2 and VARC-3 criteria [21,22]. All TAVR-related complications (according VARC-2
148 and VARC-3 definition both separately and then globally considered) were divided by intra- and
149 post-procedural. Time delay between the end of TAVR procedure and the first post-procedural
150 complication occurrence was also registered.

151 Patients' population was retrospectively divided according to FT (minutes) tertiles and than by
152 enrollment-time tertiles in order to study FT and radiation dose (RD) during TAVR learning
153 curves.

154

155 *2.2. Statistical analysis*

156 Statistical analysis was performed using SigmaStat 3.5, SPSS 25.0 and STATA 13.0 softwares.
157 Continuous variables were expressed as the mean \pm standard deviation and median (interquartile
158 ranges) of absolute numbers; categorical variables were expressed as frequencies and
159 percentages. As appropriate, comparisons were made by t-test, Mann Whitney's U-test, one way
160 ANOVA, ANOVA on ranks, Fisher's exact test or χ^2 test. Pairwise multiple comparisons after

161 ANOVAs were conducted through Holm-Sidak or Dunn's test as properly indicated by
162 definitions. The normal distribution was assessed with Kolmogorov-Smirnov tests. A receiver-
163 operating characteristic (ROC) curve analysis was built in order to establish the threshold levels
164 of FT that provided the best cut-off for the absence of ES according to VARC-2 and VARC-3
165 definitions. Area under the curve (AUC) values were calculated with confidence intervals (CIs)
166 through concordance statistics to measure test accuracy. The DeLong test was used to identify
167 AUC standard errors. The calibration of FT was evaluated by comparing the mean predicted
168 probability and the mean observed frequency of absence of ES with goodness-of-fit R-squared
169 and Cochran-Armitage tests, calibration plots and estimation of a calibration slope. After this,
170 new optimal cut-off points for the absence of ES were selected using Youden's tests, reporting
171 Youden's indexes: we evaluated sensitivity and specificity according to these new cut-off points.
172 The relationship between FT and the absence of ES was also analysed after propensity score
173 matching (PSM) including as covariates those factors that were considered to increase the time
174 of the procedure: pre-dilatation, post-dilatation, intra-procedural complications, self expandable
175 valve implantation, pre-TAVR ejection-fraction, pre-TAVR maximum transaortic gradient,
176 trans-apical and direct aortic access. All statistical tests were two-sided. For all tests, a p-value
177 <0.05 was considered statistically significant.

178

179 **3. Results**

180 *3.1. Baseline Characteristics*

181 Patients' population was divided according to FT (minutes) tertiles: 1st group 13.94 ± 2.93 min,
182 2nd group 21.31 ± 1.99 min and 3rd group 38.31 ± 18.83 min.

183 All clinical and preprocedural data of the study population are shown in Table 1.

184 No statistically significant differences were found in terms of preprocedural characteristics like
185 patients' characteristics, previous cardiovascular history, comorbidities and mortality risk scores.
186 Only echocardiographics parameters like left ventricular ejection fraction ($p < 0.001$) and
187 maximum aortic gradient ($p = 0.032$) were significantly different between the three groups.

188

189 3.2. Procedural characteristics

190 All procedural, post-procedural data and outcomes are shown in Table 2.

191 Some procedural details, such as transfemoral access ($p = 0.005$), predilatation ($p < 0.001$), self-
192 expandable bioprosthesis ($p = 0.011$), valve size > 26 mm ($p = 0.0048$), postdi-latation ($p < 0.001$),
193 contrast mean (CM) amount ($p < 0.001$) and RD ($p < 0.001$) were significantly associated with FT.

194 With respect to complications according to VARC-3 criteria, FT was significantly associated
195 with bleedings ($p < 0.001$), transfusions ($p < 0.001$), vascular complications ($p < 0.001$),
196 percutaneous closure device failure ($p = 0.005$), cardiac arrest during the procedure ($p < 0.001$)
197 and acute myocardial infarction ($p = 0.009$). FT resulted also significantly linked ($p = 0.016$) with
198 post-procedural complications and patients in the longest FT group experienced a complication
199 earlier than those with shorter FT ($p = 0.049$). Moreover, longer hospitalizations were
200 significantly associated with higher FT during the TAVR procedure ($p < 0.001$).

201 Furthermore, figure 1 shows the variation of FT and RD after splitting the population into tertiles
202 according to the period of enrollment.

203 There was no significant difference of FT across the tertiles of enrollment-time (23.54 ± 15.41 ;
204 24.92 ± 18.13 ; 24.74 ± 12.01 min; $p = 0.371$). On the other hand, there is a significant variation of
205 RD that spanned along the study time ($p < 0.001$). RD significantly decreased between first and
206 second enrolling time tertile, while the slight RD increase between second and third tertiles

207 resulted not significant after pairwise comparisons (1143.96 ± 82.72 vs 1449.70 ± 73.23 mGY;
208 $p=0.175$).

209 3.3. *Outcomes*

210 Table 2 also shows outcomes incidence and its relationship with FT. Concerning outcomes
211 according to VARC-3 criteria, higher FT was significantly associated with lower TS and DS
212 ($p < 0.001$ and $p = 0.021$ respectively) and higher absence of ES ($p = 0.013$). Also considering
213 VARC-2 criteria, the absence of ES was significantly associated with the fluoroscopy time
214 ($p < 0.001$).

215 Furthermore, table 3 describes the relation between FT and outcomes, intended as TS, DS and
216 ES according to VARC-3 criteria and ES according to VARC-2 criteria, after PSM. PSM was
217 performed including, as covariates, all those variables that were considered to be likely to
218 influence FT: pre-dilatation, post-dilatation, intraprocedural complications (according each
219 VARC-2 or -3 outcome), self-expandable valve implantation, pre-TAVR ejection fraction, pre-
220 TAVR maximum transaortic gradient, other vascular access than femoral one. After PSM, higher
221 FT was still significantly related with the absence of TS ($p = 0.001$), DS ($p < 0.001$) and ES ($p =$
222 0.035), according to VARC-3 criteria, and the absence of ES ($p = 0.046$) according to VARC-2
223 criteria.

224 Moreover, the ROC analysis showed a significant correlation between FT and these outcomes
225 (Table 4, Figure 2). Nevertheless, based on the AUC of the cut-off values established with the
226 highest Youden's indexes, a good performance was demonstrated only in detecting TS (Cut-off
227 27.8 ± 0.04 min) according to VARC-3 criteria and ES (Cut-off 30.1 ± 0.03 min) according to
228 VARC-2 criteria (ES-VARC-3: AUC 0.545, 95% CI 0.518–0.571, sensitivity 29.5%, specificity
229 80%, $p = 0.008$; DS-VARC-3: AUC 0.608, 95% CI 0.581–0.633, sensitivity 60.56%, specificity

230 57.89%, $p < 0.001$, TS-VARC-3: AUC 0.680, 95% CI 0.654–0.704, sensitivity 54.17%,
231 specificity 76.21%, $p < 0.001$; ES-VARC-2: AUC 0.628, 95% CI 0.601–0.654, sensitivity
232 41.28%, specificity 81.53%, $p < 0.001$).

Table 1. Baseline characteristics of the study population according to FT tertiles

Variable	All	Fluoroscopy Time			p
		1 st	2 nd	3 rd	
<i>Patients characteristics</i>					
Age (years)	80.86±5.71	80.72±5.59	80.61±6.13	81.17±5.48	0.403
Male	785/1797 (43.68%)	206/491 (41.95%)	210/438 (47.94%)	220/463 (47.52%)	0.118
Body Mass Index (kg/m ²)	27.34±4.73	27.34±4.77	27.20±4.32	27.48±5.07	0.802
Hypertension	1690/1785 (94.68%)	453/486 (93.21%)	409/437 (93.59%)	433/457 (94.75%)	0.597
Diabetes mellitus	577/1788 (32.27%)	160/488 (32.79%)	149/437 (34.10%)	154/458 (33.62%)	0.912
Insulin	238/1759 (13.53%)	65/483 (13.46%)	71/424 (16.74%)	72/447 (16.11%)	0.339
Dyslipidemia	1170/1786 (65.51%)	320/487 (65.71%)	296/437 (67.73%)	304/457 (66.52%)	0.807
Smoking	122/1744 (6.99%)	40/483 (8.28%)	23/421 (5.46%)	28/436 (6.42%)	0.227
Anemia	977/1782 (54.83%)	254/490 (51.84%)	239/435 (54.94%)	267/459 (58.17%)	0.147
COPD	452/1786 (25.31%)	122/487 (25.01%)	111/437 (25.40%)	138/458 (30.13%)	0.151
Neurological dysfunction	146/1759 (8.30%)	36/483 (7.45%)	35/427 (8.20%)	35/451 (7.76%)	0.916
Severe liver disease	41/1783 (2.30%)	13/488 (%)	10/435 (%)	10/457 (%)	0.882
PAD	421/1758 (23.95%)	128/483 (26.50%)	90/428 (21.03%)	109/451 (24.17%)	0.155
Carotid stenosis ≥50%	45/1354 (3.23%)	6/297 (%)	10/338 (%)	15/345 (%)	0.235
Critical preoperative state	66/1779 (3.71%)	18/485 (3.71%)	23/435 (5.29%)	18/456 (3.95%)	0.454
CAD history	448/1784 (25.11%)	125/488 (25.61%)	109/436 (25.00%)	130/456 (28.51%)	0.441
Prior myocardial infarction	255/1786 (14.28%)	76/488 (15.57%)	64/436 (14.68%)	86/457 (18.82%)	0.208
Prior cardiac surgery	253/1787 (14.16%)	68/489 (13.91%)	68/437 (15.56%)	72/458 (15.72%)	0.687
Prior myocardial revascularization	406/1791 (22.68%)	119/489 (24.33%)	95/437 (21.74%)	118/459 (25.71%)	0.370
PCI	248/1791 (13.85%)	76/489 (15.54%)	48/437 (10.98%)	74/459 (16.12%)	0.056
CABG	92/1791 (5.14%)	28/489 (5.73%)	27/437 (6.18%)	26/459 (5.66%)	0.938
PCI + CABG	66/1791 (3.69%)	15/489 (3.07%)	20/437 (4.58%)	18/459 (3.92%)	0.486
Myocardial revascularization for TAVR	271/1791 (15.13%)	67/486 (13.79%)	54/437 (12.36%)	65/463 (14.04%)	0.728
PCI	266/1791 (14.85%)	66/486 (13.58%)	53/437 (12.13%)	62/463 (13.39%)	0.781
CABG	4/1791 (0.22%)	1/486 (0.21%)	1/437 (0.23%)	2/463 (0.43%)	0.778
PCI + CABG	1/1791 (0.05%)	0/486 (0.00%)	0/437 (0.00%)	1/463 (0.22%)	0.369
Residual significant CAD	214/1782 (12.01%)	60/483 (12.42%)	48/437 (12.34%)	49/459 (10.67%)	0.666

during TAVR					
Prior PM/ICD/CRT implantation	222/1772 (12.53%)	57/485 (11.75%)	49/433 (11.32%)	62/454 (13.66%)	0.522
NYHA functional class III-IV	1475/1786 (82.59%)	402/487 (82.55%)	355/437 (81.24%)	356/457 (77.90%)	0.181
CKD	743/1797 (41.35%)	212/491 (43.18%)	178/438 (40.64%)	200/463 (43.20%)	0.671
<i>Electrocardiography</i>					
Sinus rhythm	1462/1788 (81.77%)	390/488 (79.92%)	354/437 (81.01%)	383/458 (83.62%)	0.325
Atrial fibrillation / flutter	326/1788 (18.23%)	98/488 (20.08%)	83/437 (18.99%)	75/458 (16.38%)	0.325
PM-induced rhythm	94/1788 (5.26%)	31/488 (6.35%)	24/437 (5.49%)	24/458 (5.24%)	0.741
<i>Echocardiography</i>					
LVEF (%)	53.34±10.21	54.22±10.81	52.88±10.47	52.33±9.77	<0.001
Maximum aortic gradient (mmHg)	75.67±21.22	73.43±20.45	77.38±20.00	76.33±22.69	0.032
Mean aortic gradient (mmHg)	46.40±14.33	45.27±14.29	47.21±13.23	46.92±14.93	0.074
Moderate-to-severe mitral regurgitation	679/1678 (40.46%)	175/455 (38.46%)	179/407 (43.98%)	194/429 (45.22%)	0.095
Pulmonary arterial systolic pressure (mmHg)	40.22±13.37	40.23±12.47	39.72±12.84	40.07±12.83	0.834
<i>Mortality risk scores</i>					
Logistic EuroSCORE	16.14±12.31	16.04±12.76	15.94±12.18	17.49±13.55	0.068
EuroSCORE II	5.79±12.75	5.61±5.84	5.26±5.35	6.04±6.79	0.283
STS-PROM	4.60±3.55	4.70±3.60	4.47±3.45	4.96±4.32	0.077
STS-PROM≥8	176/1779 (9.90%)	45/486 (9.26%)	44/435 (10.11%)	60/453 (13.24%)	0.122

234 COPD = chronic obstructive pulmonary disease; PAD = peripheral artery disease; CAD = coronary artery disease; PCI = percutaneous coronary intervention;
235 CABG = coronary artery by-pass grafting; TAVR = transcatheter aortic valve replacement; PM = pacemaker; ICD = implantable cardioverter-defibrillator; CRT
236 = cardiac resynchronization therapy; NYHA = New York Heart Association; CKD = chronic kidney disease; LVEF = left ventricular ejection fraction;
237 EuroSCORE = european system for cardiac operative risk evaluation; STS-PROM = Society of Thoracic Surgery predictive risk of mortality.
238
239

Table 2. Procedural features and outcomes according to FT tertiles

Variable	All	Fluoroscopy Time			
		1 st	2 nd	3 rd	p
<i>Procedural details</i>					
Transfemoral access route	1703/1797 (94.77%)	444/491 (90.43%)	416/438 (94.98%)	440/463 (95.03%)	0.005

Other access routes	94/1797 (5.23%)	47/491 (9.57%)	22/438 (5.02%)	23/463 (4.97%)	0.005
Trans-subclavian	27/1797 (1.57%)	9/491(1.83%)	6/438 (1.37%)	12/463 (2.59%)	0.404
transapical	57/1797 (3.17%)	36/491 (7.33%)	10/438 (2.28%)	9/463 (1.94%)	<0.001
direct aortic	8/1797 (0.44%)	1/491(0.20%)	6/438 (1.37%)	1/463 (0.22%)	0.029
Orotracheal intubation	233/1796 (12.97%)	73/491 (14.87%)	66/437 (15.10%)	90/463 19.44%	0.107
Valve-in-valve	73/1794 (4.07%)	16/491 (3.26%)	20/437 (4.58%)	27/461 (5.86%)	0.157
Pre-dilation	827/1784 (46.36%)	186/489 (38.04%)	248/436 (56.88%)	282/456 (61.84%)	<0.001
Valve kind					
balloon-expandable	551/1797 (30.66%)	190/491 (38.70%)	153/438 (34.93%)	130/463 (28.08%)	0.002
self-expandable	1124/1797 (62.55%)	266/491 (54.17%)	248/438 (56.62%)	294/463 (63.50%)	0.011
others	122/1797 (6.79%)	35/491 (7.13%)	37/438 (8.45%)	39/463 (8.42%)	0.691
Valve Size >26 mm	722/1793 (40.27%)	175/489 (35.79%)	166/438 (37.90%)	200/461 (43.38%)	0.048
Post-dilation	479/1795 (26.68%)	97/491 (19.76%)	112/436 (25.69%)	145/463 (31.32%)	<0.001
CM volume (mL)	149.97±76.36	130.431±54.03	161.14±67.22	197.61±96.94	<0.001
Radiation Dose (mGY)	1366.18±1241.57	1070.68±1051.40	1381.24±1070.11	2112.15±1748.60	<0.001
Complications and outcomes (VARC-3)					
AKI	272/1714 (15.87%)	70/472 (14.83%)	50/420 (11.90%)	72/433 (16.63%)	0.142
CVVH	41/1730 (2.37%)	10/476 (2.10%)	8/420 (1.90%)	15/438 (3.42%)	0.288
Chronic hemodialysis	9/1667 (0.54%)	3/460 (0.65%)	2/409 (0.49%)	4/423 (0.95%)	0.724
Bleeding (VARC-3)	588/1399 (48.03%)	124/343 (36.15%)	139/313 (44.41%)	214/362 (59.12%)	<0.001
Type 1	192/ (13.72%)	34/343 (9.91%)	55/313 (17.57%)	72/362 (19.89%)	<0.001
Type 2	307/1399 (21.94%)	67/343 (19.53%)	67/313 (21.41%)	102/362 (28.18%)	0.017
Type 3-5	89/1399 (6.36%)	23/343 (6.71%)	17/313 (5.43%)	40/362 (11.05%)	0.016
BARC≥3	561/1773 (32.37%)	124/477 (26.00%)	117/424 (27.59%)	208/449 (46.32%)	<0.001
Need of transfusion	298/1721 (17.31%)	61/475 (12.84%)	65/419 (15.51%)	108/442 (24.43%)	<0.001
1 unit	140/1721 (8.13%)	30/475 (6.32%)	31/419 (7.40%)	52/442 (11.76%)	0.008
2 units	106/1721 (6.16%)	23/475 (4.84%)	23/419 (5.49%)	38/442 (8.60%)	0.046
>2 units	52/1721 (3.02%)	8/475 (1.68%)	11/419 (2.62%)	18/442 (4.07%)	0.086
Vascular complications	286/1765 (16.20%)	59/484 (12.19%)	57/436 (13.07%)	118/455 (25.93%)	<0.001
minor	170/1765 (9.63%)	41/484 (8.47%)	34/436 (7.80%)	65/455 (14.29%)	0.002
major	116/1765 (6.57%)	18/484 (3.72%)	23/436 (5.27%)	53/455 (11.65%)	<0.001
Access-site related vascular complications	224/339 (66.08%)	22/69 (31.88%)	43/86 (50.00%)	47/137 (34.31%)	0.029

PCD failure	101/1556 (6.49%)	20/404 (4.72%)	22/373 (5.90%)	40/387 (10.34%)	0.005
At least moderate residual aortic regurgitation	129/1562 (8.26%)	26/412 (6.31%)	30/377 (7.96%)	38/398 (9.55%)	0.223
Permanent PM implantation	226/1572 (14.38%)	51/419 (12.17%)	64/484 (16.67%)	60/381 (15.75%)	0.163
ECM/cardiac arrest	66/1713 (3.85%)	15/473 (3.17%)	7/425 (1.65%)	34/440 (7.73%)	<0.001
New-onset atrial fibrillation/flutter	124/1412 (8.78%)	33/375 (8.80%)	25/343 (7.29%)	33/376 (8.78%)	0.707
Acute myocardial infarction	19/1774 (1.07%)	2/486 (0.41%)	3/437 (0.69%)	11/454 (2.42%)	0.009
Stroke/TIA	34/1773 (1.92%)	6/487 (1.23%)	8/437 (1.83%)	7/453 (1.54%)	0.759
Hospital length of stay (days)	5.73±9.63	4.99±3.52	5.53±3.93	6.34±4.46	<0.001
Hospital length of stay>5days	627/1722 (36.41%)	139/472 (29.45%)	160/424 (37.74%)	194/431 (45.01%)	<0.001
Technical success	1612/1752 (92.01%)	456/480 (95.00%)	406/431 (94.20%)	382/453 (84.33%)	<0.001
Device success	1562/1764 (88.55%)	442/485 (91.13%)	383/431 (88.86%)	385/451 (85.37%)	0.021
Periprocedural mortality	43/1734 (2.48%)	10/475 (2.10%)	10/423 (2.36%)	19/452 (4.21%)	0.118
Mortality at one year (F-U)	59/1686 (3.50%)	19/465 (4.09%)	10/413 (2.42%)	20/432 (4.63%)	0.212
Early safety absence (VARC-2)	222/1732 (12.82%)	42/477 (8.80%)	43/426 (10.09%)	87/449 (19.38%)	<0.001
Early safety absence (VARC-3)	559/1732 (32.27%)	141/477 (29.56%)	115/426 (26.99%)	161/449 (35.86%)	0.013
Post-procedural complications (VARC-2 and VARC-3)	427/839 (50.89%)	91/203 (44.83%)	100/188 (53.19%)	146/250 (58.40%)	0.016
Complication time-delay (days) from TAVR	3.44±39.39	3.13±18.55	6.99±79.80	2.55±11.97	0.049

240 AKI = acute kidney injury; CVVH = continuous venovenous haemofiltration; PCD = percutaneous closure device; ECM = external cardiac massage; TIA =
241 transient ischemic attack; F-U = follow up; VARC = Valve Academic Research Consortium

242

243

244

245

246

247

248

249 **Table 3. Relationship between fluoroscopy time and outcomes before and after propensity score matching (PSM)**

Variable	Early Safety (VARC-3)		p	T-statistic Yes
	Yes	No		
Fluoroscopy Time min (unmatched)	23.58±1.80	28.23±1.80	<0.001	23.58±1.80
Fluoroscopy Time min (matched after PSM*)	24.09±3.17	28.23±3.17	0.035	24.09±3.17
	Device Success (VARC-3)		p	
	Yes	No		
Fluoroscopy Time min (unmatched)	23.70±1.93	31.95±1.93	<0.001	4.27
Fluoroscopy Time min (matched after PSM*)	22.83±2.76	32.23±2.76	0.007	3.41
	Technical Success		p	
	Yes	No		
Fluoroscopy Time min (unmatched)	23.82±2.32	37.99±2.32	<0.001	2.58
Fluoroscopy Time min (matched after PSM*)	22.01±4.23	37.99±4.23	0.001	1.90
	Early Safety (VARC-2)		p	
	Yes	No		
Fluoroscopy Time min (unmatched)	33.72±2.05	23.72±3.05	<0.001	4.87
Fluoroscopy Time min (matched after PSM*)	33.72±3.10	22.11±3.10	0.046	3.74

250

251

252

253

254

255

256

257

258


259

260 **Table 4. ROC analysis of VARC-2 and VARC-3 outcomes according to FT**

261

	AUC ± DeLong standard error	95% CI	Asymptotic significance	Cut-off	Youden index	Sensitivity (%)	Specificity (%)	Accuracy (%)	LR-/LR+	Adjusted R-square	262 Slope 263 264
No Early Safety (VARC-2)	0.628±0.024	0.601-0.654	<0.001	30.1±0.03	0.229	41.28	81.53	76.41%	0.72-2.23	0.032	265 266
No Early Safety (VARC-3)	0.545±0.017	0.518-0.571	0.008	30.00±0.02	0.108	29.50	80.86	65.01%	0.87-1.54	0.011	267 268
No Device Success (VARC-2)	0.590±0.024	0.564-0.616	<0.001	22±0.04	0.158	58.60	56.28	56.55%	0.73-1.34	0.009	269 270
No Device Success (VARC-3)	0.608±0.021	0.581-0.633	<0.001	22±0.03	0.195	60.56	57.89	58.40%	0.78-1.44	0.026	270 0.948 271
No Technical Success (VARC-3)	0.680±0.028	0.654-0.704	<0.001	27.8±0.04	0.305	54.17	76.21	74.27%	0.60-2.27	0.046	272 0.886 273 274

275 VARC = Valve Academic Research Consortium; AUC = area under the curve; CI = confidence index.




276

277 **Figure 1.** TAVR learning curve. Fluoroscopy time and Radiation dose (mean and standard

278 deviation) according to TAVR enrollment time tertiles (1st tertile: 598 patients from April 2011

279 to September 2017; 2nd tertile: 600 patients from October 2017 to November 2020; 3rd tertile:



280 59

281 **Figure 2.** Absence of ES, DS and TS according to FT: ROC curve analysis.9 patients from
282 December 2020 to april 2023). NS: not significant.

283

284

285 **4. Discussion**

286 The main findings of our study can be summarized as follows: 1) longer FT during TAVR is
287 related to more complex procedure; 2) short-term outcomes after TAVR are related with FT and
288 this association persists after PSM; 3) the cut-offs identified after ROC analysis have sufficient
289 accuracy to detect VARC-3 TS and VARC-2 ES; 4) the variation over time of FT is non
290 significantly related with TAVR learning curve.

291 Our study is the first large TAVR cohort in which has been investigated the relationship between
292 FT and short-term outcomes after the last updated consensus document VARC-3 [22]. Previous
293 studies have demonstrated that prolonged FT is associated with more complex lesions treated in
294 percutaneous coronary intervention [23-25]. In our analysis a longer FT is associated with
295 transfemoral access approach and a more challenging procedure: need of pre-dilatation and post-
296 dilatation, self-expandable valve implantation, higher CM amount used and higher radiation dose
297 produced during the procedure. However, the higher length of FT when transfemoral access is
298 used instead of a surgical approach (like trans-apical and trans-subclavian) is easily explained by
299 the fact that in the first case the management of the access is completely cine-fluoroscopic
300 guided in the majority of procedures.

301 To date, no study analyzed the relationship between FT and short-term outcomes (according
302 VARC-2 and -3 definitions) in TAVR. Only radiation exposure during the procedure has been
303 investigated and has been shown to be comparable to percutaneous coronary intervention of
304 moderate complexity [18-20]. Unlike radiation exposure, FT is independent by biometric
305 parameters such as BMI. Interestingly, in our study the absence of all short-term outcomes
306 (VARC-3 TS, DS and ES and VARC-2 ES) is significantly associated with longer FT and this
307 association persists after PSM including as covariates all variables that could influence the length

308 of the procedure, including intra-procedural complications. FT appears to be an independent
309 predictor of short-term TAVR-related post-procedural complications. This could be explained by
310 the fact that in interventional cardiology the less procedures last, the fewer are the complications
311 and consequently the better are the outcomes.

312 However, although the ROC analysis showed a significant correlation between the FT and these
313 outcomes, the identified cut-offs do not have adequate diagnostic accuracy in adjudicating DS
314 and ES according to VARC-3 criteria, due to the fact that their AUC was never above 0.6.
315 Conversely, the cut-offs of 27.8 ± 0.04 min for TS according to VARC-3 and of 30.1 ± 0.03 for ES
316 according to VARC-2 have adequate diagnostic accuracy. These values show that when the FT
317 lasts more than 30 minutes, it is more likely that the patient might have to experience technical
318 failure at the exit of the catheterization laboratory or might have short-term complications
319 according VARC-2 and VARC-3 definitions.

320 The reason why this cut-off is able to predict the absence of ES-VARC-2 instead of ES VARC-3
321 can properly be explained by the possible limits of new VARC-3 criteria: the more complications
322 are included in this composite endpoint, the more its diagnostic performance will decrease.
323 Indeed, as previously reported, even the accuracy of the mortality risk score is lower with
324 VARC-3 than with VARC-2 criteria [26].

325 Finally, looking at TAVR learning curve (Figure 1), there was no significant variation in FT,
326 while a significant reduction of RD administered during the period of enrollment resulted
327 significant only between the first and the second tertile of en-rollment period. This finding could
328 be explained by the fact that the first tertile of enrollment, covering about 7 years, spanned for a
329 longer time than the second and the third ones. So the first tertile of enrollment comprehends the
330 most of the learning curve. The RD reduction is maybe related to technological advancements of

331 the newer radiological angiographers. Another explanation is that the majority of invasive
332 coronary angiography were performed simultaneously with TAVR in the third tertile of
333 enrollment-time. Thus, even though the operators improved their skills there wasn't a decrease of
334 both FT and RD between the second and third period of TAVR enrollment due to the fact that
335 more procedures were performed at the same time. However our data showed no significant
336 increase in the revascularization rate during TAVR according to FT tertiles, so an indirect
337 linkage between FT and myocardial injury related to myocardial revascularization during TAVR
338 could be excluded.

339

340 **5. Limitations**

341 Although it was obtained from a prospectively collected database, this is an unspecified post-hoc
342 analysis. Therefore, we cannot exclude that potential confounding factors not considered in the
343 model may have influenced the results. The effect of a learning curve and changes in treatment
344 strategy is also heterogeneous, as the study spanned more than a decade. Furthermore, we
345 believe that aspects of management not controlled or specified may have been a source of bias.
346 Finally, an independent committee did not adjudicate all clinical events that were site-referred.

347

348 **6. Conclusions**

349 FT is an easily available parameter during TAVR. This is the first study that evaluated the
350 relationship between FT and short-term outcomes after TAVR. Longer FT is related to peri-
351 procedural and short-term outcomes after TAVR, especially in more complex procedures. This
352 relation is independent from intra-procedural complications after PSM analysis. A FT duration of
353 more than 30 minutes has an adequate accuracy in identifying VARC-3 technical failure and

354 absence of VARC-2 ES. Defining ES according to the most recent VARC-3 consensus document
355 invalidates the accuracy of this relation, probably because of the inclusion of additional frequent
356 adverse events such as permanent PM implantation.

357

358 **Acknowledgments:** Francesco Spione has been supported by a research grant provided by the
359 Cardiopath PhD program.

360 **Acknowledgment of grant support:** none.

361

362 **Data Availability Statement:** Data are accessible with the article (raw data are available upon
363 individual request).

364 REFERENCES

365 1. Smith, C.R.; Leon, M.B.; Mack, M.J.; Miller, D.C.; Moses, J.W.; Svensson, L.G.; Tuzcu,
366 E.M.; Webb, J.G.; Fontana, G.P.; Makkar, R.R.; et al. Transcatheter versus surgical aortic-valve
367 replacement in high-risk patients. *N Engl J Med* 2011, 364, 2187-2198,
368 doi:10.1056/NEJMoa1103510.

369 2. Lefèvre, T.; Kappetein, A.P.; Wolner, E.; Nataf, P.; Thomas, M.; Schächinger, V.; De
370 Bruyne, B.; Eltchaninoff, H.; Thielmann, M.; Himbert, D.; et al. One year follow-up of the multi-
371 centre European PARTNER transcatheter heart valve study. *Eur Heart J* 2011, 32, 148-157,
372 doi:10.1093/eurheartj/ehq427.

373 3. Eltchaninoff, H.; Prat, A.; Gilard, M.; Leguerrier, A.; Blanchard, D.; Fournial, G.; Lung,
374 B.; Donzeau-Gouge, P.; Tribouilloy, C.; Debrux, J.L.; et al. Transcatheter aortic valve
375 implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards)
376 registry. *Eur Heart J* 2011, 32, 191-197, doi:10.1093/eurheartj/ehq261.

- 377 4. Thomas, M.; Schymik, G.; Walther, T.; Himbert, D.; Lefèvre, T.; Treede, H.; Eggebrecht,
378 H.; Rubino, P.; Michev, I.; Lange, R.; et al. Thirty-day results of the SAPIEN aortic
379 Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter
380 aortic valve implantation using the Edwards SAPIEN valve. *Circulation* 2010, 122, 62-69,
381 doi:10.1161/circulationaha.109.907402.
- 382 5. Rodés-Cabau, J.; Webb, J.G.; Cheung, A.; Ye, J.; Dumont, E.; Feindel, C.M.; Osten, M.;
383 Natarajan, M.K.; Velianou, J.L.; Martucci, G.; et al. Transcatheter aortic valve implantation for
384 the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive
385 surgical risk: acute and late outcomes of the multicenter Canadian experience. *J Am Coll Cardiol*
386 2010, 55, 1080-1090, doi:10.1016/j.jacc.2009.12.014.
- 387 6. Petronio, A.S.; De Carlo, M.; Bedogni, F.; Marzocchi, A.; Klugmann, S.; Maisano, F.;
388 Ramondo, A.; Ussia, G.P.; Ettori, F.; Poli, A.; et al. Safety and efficacy of the subclavian
389 approach for transcatheter aortic valve implantation with the CoreValve revalving system. *Circ*
390 *Cardiovasc Interv* 2010, 3, 359-366, doi:10.1161/circinterventions.109.930453.
- 391 7. Leon, M.B.; Smith, C.R.; Mack, M.; Miller, D.C.; Moses, J.W.; Svensson, L.G.; Tuzcu,
392 E.M.; Webb, J.G.; Fontana, G.P.; Makkar, R.R.; et al. Transcatheter aortic-valve implantation for
393 aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010, 363, 1597-1607,
394 doi:10.1056/NEJMoa1008232.
- 395 8. Himbert, D.; Descoutures, F.; Al-Attar, N.; Iung, B.; Ducrocq, G.; Détaint, D.; Brochet,
396 E.; Messika-Zeitoun, D.; Francis, F.; Ibrahim, H.; et al. Results of transfemoral or transapical
397 aortic valve implantation following a uniform assessment in high-risk patients with aortic
398 stenosis. *J Am Coll Cardiol* 2009, 54, 303-311, doi:10.1016/j.jacc.2009.04.032.

- 399 9. Piazza, N.; Grube, E.; Gerckens, U.; den Heijer, P.; Linke, A.; Luha, O.; Ramondo, A.;
400 Ussia, G.; Wenaweser, P.; Windecker, S.; et al. Procedural and 30-day outcomes following
401 transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving
402 system: results from the multicentre, expanded evaluation registry 1-year following CE mark
403 approval. *EuroIntervention* 2008, 4, 242-249, doi:10.4244/eijv4i2a43.
- 404 10. Grube, E.; Buellesfeld, L.; Mueller, R.; Sauren, B.; Zickmann, B.; Nair, D.; Beucher, H.;
405 Felderhoff, T.; Iversen, S.; Gerckens, U. Progress and current status of percutaneous aortic valve
406 replacement: results of three device generations of the CoreValve Revalving system. *Circ*
407 *Cardiovasc Interv* 2008, 1, 167-175, doi:10.1161/circinterventions.108.819839.
- 408 11. Leon, M.B.; Smith, C.R.; Mack, M.J.; Makkar, R.R.; Svensson, L.G.; Kodali, S.K.;
409 Thourani, V.H.; Tuzcu, E.M.; Miller, D.C.; Herrmann, H.C.; et al. Transcatheter or Surgical
410 Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med* 2016, 374, 1609-1620,
411 doi:10.1056/NEJMoa1514616.
- 412 12. Mack, M.J.; Leon, M.B.; Thourani, V.H.; Makkar, R.; Kodali, S.K.; Russo, M.; Kapadia,
413 S.R.; Malaisrie, S.C.; Cohen, D.J.; Pibarot, P.; et al. Transcatheter Aortic-Valve Replacement
414 with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med* 2019, 380, 1695-1705,
415 doi:10.1056/NEJMoa1814052.
- 416 13. D'Errigo, P.; Barbanti, M.; Ranucci, M.; Onorati, F.; Covello, R.D.; Rosato, S.;
417 Tamburino, C.; Santini, F.; Santoro, G.; Seccareccia, F. Transcatheter aortic valve implantation
418 versus surgical aortic valve replacement for severe aortic stenosis: results from an intermediate
419 risk propensity-matched population of the Italian OBSERVANT study. *Int J Cardiol* 2013, 167,
420 1945-1952, doi:10.1016/j.ijcard.2012.05.028.

- 421 14. Thyregod, H.G.; Steinbrüchel, D.A.; Ihlemann, N.; Nissen, H.; Kjeldsen, B.J.; Petursson,
422 P.; Chang, Y.; Franzen, O.W.; Engstrøm, T.; Clemmensen, P.; et al. Transcatheter Versus
423 Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year
424 Results From the All-Comers NOTION Randomized Clinical Trial. *J Am Coll Cardiol* 2015, 65,
425 2184-2194, doi:10.1016/j.jacc.2015.03.014.
- 426 15. Popma, J.J.; Deeb, G.M.; Yakubov, S.J.; Mumtaz, M.; Gada, H.; O'Hair, D.; Bajwa, T.;
427 Heiser, J.C.; Merhi, W.; Kleiman, N.S.; et al. Transcatheter Aortic-Valve Replacement with a
428 Self-Expanding Valve in Low-Risk Patients. *N Engl J Med* 2019, 380, 1706-1715,
429 doi:10.1056/NEJMoa1816885.
- 430 16. Chambers, C.E.; Fetterly, K.A.; Holzer, R.; Lin, P.J.; Blankenship, J.C.; Balter, S.;
431 Laskey, W.K. Radiation safety program for the cardiac catheterization laboratory. *Catheter*
432 *Cardiovasc Interv* 2011, 77, 546-556, doi:10.1002/ccd.22867.
- 433 17. Little, M.P. Risks associated with ionizing radiation. *Br Med Bull* 2003, 68, 259-275,
434 doi:10.1093/bmb/ldg031.
- 435 18. Sharma, D.; Ramsewak, A.; O'Conaire, S.; Manoharan, G.; Spence, M.S. Reducing
436 radiation exposure during transcatheter aortic valve implantation (TAVI). *Catheterization and*
437 *Cardiovascular Interventions* 2015, 85, 1256-1261, doi:<https://doi.org/10.1002/ccd.25363>.
- 438 19. Daneault, B.; Balter, S.; Kodali, S.K.; Williams, M.R.; Généreux, P.; Reiss, G.R.;
439 Paradis, J.M.; Green, P.; Kirtane, A.J.; Smith, C.; et al. Patient radiation exposure during
440 transcatheter aortic valve replacement procedures. *EuroIntervention* 2012, 8, 679-684,
441 doi:10.4244/eijv8i6a106.
- 442 20. Michel, J.M.; Hashorva, D.; Kretschmer, A.; Alvarez-Covarrubias, H.A.; Mayr, N.P.;
443 Pellegrini, C.; Rheude, T.; Frangieh, A.H.; Giacoppo, D.; Kastrati, A.; et al. Evaluation of a

- 444 Low-Dose Radiation Protocol During Transcatheter Aortic Valve Implantation. *Am J Cardiol*
445 2021, 139, 71-78, doi:10.1016/j.amjcard.2020.10.035.
- 446 21. Kappetein, A.P.; Head, S.J.; Généreux, P.; Piazza, N.; van Mieghem, N.M.; Blackstone,
447 E.H.; Brott, T.G.; Cohen, D.J.; Cutlip, D.E.; van Es, G.-A.; et al. Updated standardized endpoint
448 definitions for transcatheter aortic valve implantation: the Valve Academic Research
449 Consortium-2 consensus document†. *European Heart Journal* 2012, 33, 2403-2418,
450 doi:10.1093/eurheartj/ehs255.
- 451 22. Genereux, P.; Piazza, N.; Alu, M.C.; Nazif, T.; Hahn, R.T.; Pibarot, P.; Bax, J.J.; Leipsic,
452 J.A.; Blanke, P.; Blackstone, E.H.; et al. Valve Academic Research Consortium 3: updated
453 endpoint definitions for aortic valve clinical research. *Eur Heart J* 2021, 42, 1825-1857,
454 doi:10.1093/eurheartj/ehaa799.
- 455 23. Nikolsky, E.; Pucelikova, T.; Mehran, R.; Balter, S.; Kaufman, L.; Fahy, M.; Lansky,
456 A.J.; Leon, M.B.; Moses, J.W.; Stone, G.W.; et al. An evaluation of fluoroscopy time and
457 correlation with outcomes after percutaneous coronary intervention. *J Invasive Cardiol* 2007, 19,
458 208-213.
- 459 24. Tajti, P.; Ayoub, M.; Nuehrenberg, T.; Ferenc, M.; Behnes, M.; Buettner, H.J.; Neumann,
460 F.J.; Mashayekhi, K. Association of Prolonged Fluoroscopy Time with Procedural Success of
461 Percutaneous Coronary Intervention for Stable Coronary Artery Disease with and without
462 Chronic Total Occlusion. *J Clin Med* 2021, 10, doi:10.3390/jcm10071486.
- 463 25. Ishibashi, S.; Sakakura, K.; Asada, S.; Taniguchi, Y.; Yamamoto, K.; Tsukui, T.;
464 Seguchi, M.; Jinnouchi, H.; Wada, H.; Fujita, H. Clinical Factors Associated with Long
465 Fluoroscopy Time in Percutaneous Coronary Interventions to the Culprit Lesion of Non-ST-
466 Segment Elevation Myocardial Infarction. *Int Heart J* 2021, 62, 282-289, doi:10.1536/ihj.20-634.

467 26. Iacovelli, F.; Loizzi, F.; Cafaro, A.; Burattini, O.; Salemme, L.; Cioppa, A.; Rizzo, F.;
468 Palmitessa, C.; D'Alessandro, M.; De Feo, D.; et al. Surgical Mortality Risk Scores in
469 Transcatheter Aortic Valve Implantation: Is Their Early Predictive Value Still Strong? J.
470 Cardiovasc. Dev. Dis. 2023, 10, doi:10.3390/jcdd10060244.

471

472 **LEGEND FOR TABLES AND FOR FIGURES.**

473

474 **Table 1.** Baseline characteristics of the study population according to FT tertiles.

475 COPD = chronic obstructive pulmonary disease; PAD = peripheral artery disease; CAD =
476 coronary artery disease; PCI = percutaneous coronary intervention; CABG = coronary artery by-
477 pass grafting; TAVR = transcatheter aortic valve replacement; PM = pacemaker; ICD =
478 implantable cardioverter-defibrillator; CRT = cardiac resynchronization therapy; NYHA = New
479 York Heart Association; CKD = chronic kidney disease; LVEF = left ventricular ejection
480 fraction; EuroSCORE = european system for cardiac operative risk evaluation; STS-PROM =
481 Society of Thoracic Surgery predictive risk of mortality.

482 **Table 2.** Procedural features and outcomes according to FT tertiles.

483 AKI = acute kidney injury; CVVH = continuous venovenous haemofiltration; PCD =
484 percutaneous closure device; ECM = external cardiac massage; TIA = transient ischemic attack;
485 F-U = follow up; VARC = Valve Academic Research Consortium.

486 **Table 3.** Relationship between fluoroscopy time and outcomes before and after propensity score
487 matching (PSM).


488 **Table 4.** ROC analysis of VARC-2 and VARC-3 outcomes according to FT.

489 VARC = Valve Academic Research Consortium; AUC = area under the curve; CI = confidence
490 index.

491
492 **Figure 1.** TAVR learning curve. Fluoroscopy time and Radiation dose (mean and standard
493 deviation) according to TAVR enrollment time tertiles (1st tertile: 598 patients from April 2011
494 to September 2017; 2nd tertile: 600 patients from October 2017 to November 2020; 3rd tertile:
495 599 patients from December 2020 to april 2023). NS: not significant.

496 **Figure 2.** Absence of ES, DS and TS according to FT: ROC curve analysis.

FLUOROSCOPY TIME



RADIATION DOSE

